Synergistic effects of taurine and cisplatin on lung cancer cells (A549)

Jouni F.J., Zafari J., Abbasifard M., Jafarisani M., Bagheri-Hosseinabadi Z.

Department of Biomedical Engineering, Faculty of Health, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Assistant Professor, Department of internal Medicine, school of medicine, AliIbn AbiTalib hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
School of Medicine, Shahroud University of Medicine, Shahroud, Iran
Department of Clinical Biochemistry, Faculty of Medicine and PhysiologyPharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Lung cancer is one of the most common types of cancer that causes death. In this study the effects of cisplatin, taurine and combination of these two compounds on A549 cell line were examined. A549 Cells were treated with different concentrations of taurine, cisplatin and the combination of two compounds. MTT assay, flow cytometry analysis of apoptosis and flow cytometry analysis of cell cycle were carried out. The expression of genes was examined by realtime PCR. Cisplatin and taurine reduced the viability of the A549 cell line but this effect was greater in taurine and cisplatin combination. Cells that were in G0/G1 stage increased in all treated group and this inhibition was notable in the combination group. The expression of some genes such as P53, Bax, caspase 3, caspase 9 and P14 increased. Our studies also showed that cisplatin and taurine combination was moderately synergic with Cl values ranging from X to Y for Fa 0.5. Combination of cisplatin and taurine may be effective in the cancer therapy and it can be a suitable choice for reduction of drug resistance problems and other side effects of cisplatin high dosage, but more researches are needed to be performed in this field.

Keywords: Cancer; Cell line; Cisplatin; Taurine; DrugResistance

TSitologiya i Genetika
2023, vol. 57, no. 2, 65-66

Cytology and Genetics
2023, vol. 57, no. 2, 197–206,
doi: 10.3103/S0095452723020044

Full text and supplemented materials

References

Arnesano, F., Losacco, M., and Natile, G., An updated view of cisplatin transport, Eur. J. Inorg. Chem., 2013, no. 15, pp. 2701–2711.

Basu, A. and Krishnamurthy, S., Cellular responses to cisplatin-induced DNA damage, J. Nucleic Acids, 2010, vol. 2010, p. 201367.

Beretta, G.L., Gatti, L., Tinelli, S., Corna, E., Colangelo, D., Zunino, F., et al., Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells, Biochem. Pharmacol., 2004, vol. 68, no. 2, pp. 283–291.

Chen, D., Milacic, V., Frezza, M., and Dou, Q.P., Metal complexes, their cellular targets and potential for cancer therapy, Curr. Pharm. Design, 2009, vol. 15, no. 7, pp. 777–791.

Chowdhury, S., Sinha, K., Banerjee, S., and Sil, P.C., Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses, Biofactors, 2016, vol. 42, no. 6, pp. 647–664.

El Agouza, I., Eissa, S., El Houseini, M., El-Nashar, D.E., and El Hameed, O.A., Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients, Angiogenesis, 2011, vol. 14, no. 3, p. 321.

Florea, A.-M. and Büsselberg, D., Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects, Cancers, 2011, vol. 3, no. 1, pp. 1351–1371.

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., et al., Molecular mechanisms of cisplatin resistance, Oncogene, 2012, vol. 31, no. 15, p. 1869.

Holzer, A.K., Katano, K., Klomp, L.W., and Howell, S.B., Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells, Clin. Cancer Res., 2004, vol. 10, no. 19, pp. 6744–6749.

Jalali, A., Zafari, J., Jouni, F.J., Abdolmaleki, P., Shirazi, F.H., and Khodayar, M.J., Combination of static magnetic field and cisplatin in order to reduce drug resistance in cancer cell lines, Int. J. Radiat. Biol., 2019, vol. 1–8.

Kim, T. and Kim, A.K., Taurine enhances anticancer activity of cisplatin in human cervical cancer cells, in Taurine 8, Springer-Verlag, 2013, pp. 189–198.

Kim, C.W., Lu, J.N., Go, S.-I., Jung, J.H., Yi, S.M., Jeong, J.-H., et al., p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax, Int. J. Oncol., 2013, vol. 43, no. 5, p. 1495–1502.

Miller, K.D., Siegel, R.L., Lin, C.C., Mariotto, A.B., Kramer, J.L., Rowland, J.H., et al., Cancer treatment and survivorship statistics, Ca-Cancer J. Clin., 2016, vol. 66, no. 4, pp. 271–289.

Nematbakhsh, M., Ashrafi, F., Pezeshki, Z., Fatahi, Z., Kianpoor, F., Sanei, M.-H., et al., A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model?, J. Nephropathol., 2012, vol. 1, no. 3, p. 190.

Saad, S.Y. and Al-Rikabi, A.C., Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats, Chemotherapy, 2002, vol. 48, no. 1, pp. 42–48.

Safaei, R. and Howell, S.B., Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs, Crit. Rev. Oncol./Hematol., 2005, vol. 53, no. 1, pp. 13–23.

Sato, S., Yamate, J., Saito, T., Hosokawa, T., Saito, S., and Kurasaki, M., Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 2002, vol. 365, no. 4, pp. 277–283.

Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al., Cancer treatment and survivorship statistics, 2012, Ca-Cancer J. Clin., 2016, vol. 62, no. 4, pp. 220–241.

Siegel, R.L., Miller, K.D., and Jemal, A., Cancer statistics, Ca-Cancer J. Clin., vol. 66, no. 1, pp. 7–30.

Smith, R.A., Andrews, K.S., Brooks, D., Fedewa, S.A., Manassaram-Baptiste, D., Saslow, D., et al., Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening, Ca-Cancer J. Clin., 2018, vol. 68, no. 4, pp. 297–316.

Tsai, C.-Y., Larson, C.A., Safaei, R., and Howell, S.B., Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4, Biochem. Pharmacol., vol. 90, no. 4, pp. 379–387.

Tu, S., Zhang, X.L., Wan, H.F., Xia, Y.Q., Liu, Z.Q., Yang, X.H., et al., Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells, Oncol. Lett., 2018, vol. 15, no. 4, pp. 5473–5480.

Vanitha, M., Baskaran, K., Periyasamy, K., Saravanan, D., Ilakkia, A., Selvaraj, S., et al., A review on the biomedical importance of taurine, Int. J. Pharm. Res. Health Sci., 2015, vol. 3, no. 3, pp. 680–686.

Vasan, N., Baselga, J., and Hyman, D.M., A view on drug resistance in cancer, Nature, 2019, vol. 575, no. 7782, pp. 299–309.

Zafari, J., Vazini, H., Javani-jouni, F., Abdolmaleki, P., Monajemi, R., Shams, E., et al., Anticancer effects of moderate static magnetic field on cancer cells in vitro, Res. Mol. Med., 2018, vol. 6, no. 3, pp. 54–64.

Zhang, X., Tu, S., Wang, Y., Xu, B., and Wan, F., Mechanism of taurine-induced apoptosis in human colon cancer cells, Acta Biochim. Biophys. Sin., 2014, vol. 46, no. 4, pp. 261–272.

Zhang, X., Lu, H., Wang, Y., Liu, C., Zhu, W., Zheng, S., et al., Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria, Int. J. Mol. Med., 2015, vol. 35, no. 1, pp. 218–226.